Skip to main content

Our Team

The Alpine BioVentures Team

Biotech companies must have the right people to succeed. Bold science, however exciting, is not enough. The Alpine BioVentures team brings our unique expertise to every investment. We have been involved in every facet of drug development and have guided products all the way from the discovery stage to regulatory approval. We have long-standing relationships with big pharma, big biotech, and Wall Street to help our companies reach their full potential.


Mitchell H. Gold, MD

Founder & Managing Partner

Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer, stemming from the loss of his 26-year old mother to metastatic breast cancer when he was four years old. This loss served as the catalyst for Dr. Gold’s career in medicine and desire to transform scientific breakthroughs into a reality for patients.

As CEO of Dendreon Corporation, Dr. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient’s own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010.

Read more

Dr. Gold was chairman and founder of Alpine Biosciences, a privately-held biotech company dedicated to developing the next generation of cancer and orphan disease treatments via a best-in-class nano-particle delivery system. Alpine Biosciences was sold to Cascadian Therapeutics (NASDAQ:CASC) in August 2014. For his contributions to science and the treatment of cancer, Dr. Gold was named a runner up to Steve Jobs and Jeff Bezos for “Smartest CEO” by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. He was voted “Entrepreneur of the Year” in the Pacific Northwest in 2011 by Ernst and Young, as well as the top influencer in medicine in 2010 by Seattle Magazine. A Chicago native, Dr. Gold graduated from the University of Wisconsin and Rush University Medical School in Chicago and was a urology resident at the University of Washington. Dr. Gold is on Twitter @Alpine_Mitch

Jay Venkatesan, MD

Managing Partner

Prior to joining Alpine Immune Sciences, Dr. Jay Venkatesan was the executive vice president and general manager of Oncothyreon, Inc (now Cascadian Therapeutics) from August 2014 to May 2015 following Oncothyreon’s acquisition of Alpine Biosciences, where he served as co-founder and CEO. Previously, Dr. Venkatesan was the founder, portfolio manager, and managing director of Ayer Capital Management, a global healthcare long-short equity fund. Prior to that, he served as a director at Brookside Capital Partners, the hedge fund group affiliated with Bain Capital, where he co-managed healthcare investments and evaluated public and private investments in all healthcare subsectors. Earlier in his career, Dr. Venkatesan was involved in healthcare venture investing at Patricof & Co. Ventures (now Apax Partners) and consulting at McKinsey & Company.

Read more

In addition, Dr. Venkatesan currently serves on the Board of Directors of Lion Biotechnologies (NASDAQ:LBIO) and Exicure Therapeutics. He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.

David D. Miller


David Miller brings 15 years of life sciences experience to Alpine BioVentures. As the former CEO of the independent research firm Biotech Stock Research, Mr. Miller’s specialty is in-depth research into the science, operations, management, and market potential of both cutting-edge science and established development-stage biotechnology companies.

Miller also co-founded with Dr. Alan Leong the Entrepreneur’s Workshop curriculum at the University of Washington – Bothell campus. The Entrepreneur’s Workshop generated stunning success for the campus and surrounding community with over 90 companies launched – generally acknowledged as the highest launch rate for an undergraduate entrepreneurship program in the nation.

Read more

  Picked by both Xconomy and FierceBiotech as one of the most influential biotech voices in social media, you can find him on Twitter @AlpineBV_Miller. Mr. Miller graduated from Western Washington University in Bellingham, WA. 

Remy Durand, PhD


Dr. Remy Durand joins Alpine BioVentures with over 10 years of experience in life sciences research, consulting, and investing.

Prior to Alpine BioVentures, Dr. Durand was a Vice President on the life sciences investment team at Frazier Healthcare Partners, one of the first dedicated healthcare investment firms. During his time at Frazier, he was a board observer or director on multiple investments including Alpine Immune Sciences (NASDAQ: ALPN), Aptinyx (NASDAQ: APTX), and Scout Bio. Earlier in his career, he was an investment professional at GE Ventures Healthcare and spent time as a management consultant with LEK Consulting, a premier strategic advisor to the life sciences industry. Dr. Durand is also currently the Vice President of Business Development at Alpine BioVentures portfolio company Alpine Immune Sciences (NASDAQ: ALPN).


Read more

Dr. Durand received his Ph.D. in Bioengineering from Stanford University, where he was a National Science Foundation Graduate Research Fellow. Dr. Durand’s doctoral research used optogenetics to map neural circuits and to understand the physiologic basis of functional neural imaging, which resulted in publications in Nature and Nature Protocols. He also holds a B.S.E. in Biomedical Engineering from Case Western Reserve University.

Questions or Comments?